Modern view on the problem of therapy of recurrent polyposis rhinosinusitis, comparative study of the effectiveness of different monoclonal antibody preparations ; Современный взгляд на проблему терапии рецидивирующего полипозного риносинусита: сравнительное исследование эффективности применения различных препаратов моноклональных антител

Authors: A. I. Kryukov, A. V. Gurov, D. S. Fomina, A. S. Tovmasyan, G. K. Rabadanov, А. И. Крюков, А. В. Гуров, Д. С. Фомина, А. С. Товмасян, Г. К. Рабаданов

Source: Meditsinskiy sovet = Medical Council; № 23 (2024); 80-86 ; Медицинский Совет; № 23 (2024); 80-86 ; 2658-5790 ; 2079-701X

Subject Terms: биологическая терапия, bronchial asthma, inhaled glucocorticosteroids, chronic polyposis rhinosinusitis, biological therapy, бронхиальная астма, ингаляционные глюкокортикостероиды, хронический полипозный риносинусит

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8830/7739; Larsen K, Tos M. Clinical course of patients with primary nasal polyps. Acta Otolaryngol. 1994;114(5):556–559. https://doi.org/10.3109/00016489409126104.; Slater A, Smallman LA, Logan AC, Drake-Lee AB. Mucociliary function in patients with nasal polyps. Clin Otolaryngol Allied Sci. 1996;21(4):343–347. https://doi.org/10.1111/j.1365-2273.1996.tb01084.x.; Носуля ЕВ, Ким ИА, Афанасьева НВ, Сумбаева ОВ. Распространенность полипозного риносинусита среди городского населения Восточной Сибири. Российская ринология. 2007;(1):4–8. Режим доступа: https://elibrary.ru/hzqvaz.; Арефьева НА, Вишняков ВВ, Вахрушев СГ. Полипозный риносинусит. Клинические рекомендации. М.; 2010.; Пискунов ГЗ. Клинические фенотипы полипозного риносинусита. Российская ринология. 2019;27(4):224–231. https://doi.org/10.17116/rosrino201927041224.; Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17–35. https://doi.org/10.1164/rccm.202109-2205PP.; Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. https://doi.org/10.2147/copd.s67283.; Геппе НА, Колосова НГ. Национальная программа «Бронхиальная астма у детей», 2012. Стратегия лечения. Consilium Medicum. Пульмонология (Прил.). 2012;(1):39–41. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2012/pulmo_2012_pril/natsionalnaya-programma-bronkhialnaya-astma-u-detey-2012-strategiya-lecheniya.; Samoliński B, Szczesnowicz-Dabrowska P. Relationship between inflammation of upper and lower respiratory airways. Otolaryngol Pol. 2002;56(1):49–55. Available at: https://pubmed.ncbi.nlm.nih.gov/12053668/.; Serrano E, Neukirch F, Pribil C, Jankowski R, Klossek JM, Chanal I, El Hasnaoui A. Nasal polyposis in France: Impact on sleep and quality of life. J Laringol Otol. 2005;119(7):543–549. https://doi.org/10.1258/0022215054352108.; Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764. https://doi.org/10.1183/09031936.04.00013904.; Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006;61(6):693–698. https://doi.org/10.1111/j.1398-9995.2006.01054.x.; Nathan RA, O Meltzer E, Derebery J, Campbell UB, Stang PE, Corrao MA et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 2008;29(6):600–608. https://doi.org/10.2500/aap.2008.29.3179.; Katelaris CH, Lee BW, Potter PC, Maspero JF, Cingi C, Lopatin A et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012;42(2):186–207. https://doi.org/10.1111/j.1365-2222.2011.03891.x.; Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW et al. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1):1. https://doi.org/10.1186/s12948-015-0008-x.; Cingi C, Yorgancioglu A, Cingi CC, Oguzulgen K, Muluk NB, Ulusoy S et al. The “physician on call patient engagement trial” (POPET): measuring the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis and asthma patients. Int Forum Allergy Rhinol. 2015;5(6):487–497. https://doi.org/10.1002/alr.21468.; Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am J Ther. 2016;23(6):e1568-e1578. https://doi.org/10.1097/mjt.0000000000000242.; Савлевич ЕЛ, Гаганов ЛЕ, Егоров ВИ, Курбачева ОМ, Герасимов АН, Шачнев КН. Сравнительное пилотное исследование эндотипов хронического полипозного риносинусита у пациентов, проживающих в разных географических регионах Российской Федерации. Иммунология. 2018;39(4):208–213. Режим доступа: https://cyberleninka.ru/article/n/sravnitelnoe-pilotnoe-issledovanie-endotipov-hronicheskogo-polipoznogorinosinusita-u-patsientov-prozhivayuschih-v-raznyh/viewer.; Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e4. https://doi.org/10.1016/j.jaci.2015.12.1324.; Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/rhin20.600.; Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol Suppl. 1995;167:17–21. Available at: https://pubmed.ncbi.nlm.nih.gov/7574265/.; Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. https://doi.org/10.1056/nejmoa1403290.; Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511. https://doi.org/10.1016/j.anai.2018.01.030.; Козлов ВС, Савлевич ЕЛ. Полипозный риносинусит. Современные подходы к изучению патогенеза, диагностике и лечению. Вестник оториноларингологии. 2015;80(4):95–99. https://doi.org/10.17116/otorino201580495-99.; Рязанцев СВ, Будковая МА. Тактика лечения полипозного риносинусита. Российская оториноларингология. 2017;(2):162–169. https://doi.org/10.18692/1810-4800-2017-2-162-169.; Лопатин АС. Современные теории патогенеза полипозного риносинусита. Пульмонология. 2003;(5):110–115. Режим доступа: https://journal.pulmonology.ru/pulm/article/view/2629/2061.; Пискунов ГЗ. Физиологическое и патофизиологическое обоснование функциональной риносинусохирургии. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018;24(1):23–28. Режим доступа: https://www.elibrary.ru/yulkqc.; Курбачева ОМ, Дынева МЕ, Ильина НИ. Дупилумаб: основные аспекты применения при T2-опосредованных заболеваниях. Медицинский cовет. 2021;(16):186–196. https://doi.org/10.21518/2079-701X-2021-16-186-196.; Hopkins C. Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60(3):162–168. https://doi.org/10.4193/Rhin21.477.; Karin J, Tim D, Gabriele H, Cardell LO, Marit W, Claus B. Type 2 inflammatory shift in chronic rhinosinusitis during 2007–2018 in Belgium. Laryngoscope. 2021;131(5):E1408–E1414. https://doi.org/10.1002/lary.29128.; Аллахверанов ДАО, Юнусов АС, Рябинин АГ. Отдаленные результаты эндоскопических методов лечения хронического полипозного риносинусита. Российская оториноларингология. 2015;(3):158–160. Режим доступа: https://cyberleninka.ru/article/n/otdalennye-rezultaty-endoskopicheskihmetodov-lecheniya-hronicheskogo-polipoznogo-rinosinusita.; Завадский АВ, Завадский НВ, Золотарева МА. Ведение послеоперационного периода у больных полипозом носа. Российская оториноларингология. 2015;(5):89–94. Режим доступа: https://www.elibrary.ru/unldtd.; Широкая АВ, Свистушкин ВМ, Шатохина СН, Шабалин ВН. Оценка эффективности лечения больных полипозным риносинуситом и прогноз его течения. Российская оториноларингология. 2013;(2):96–104. Режим доступа: https://cyberleninka.ru/article/n/otsenka-effektivnosti-lecheniyabolnyh-polipoznym-rinosinusitom-i-prognoz-ego-techeniya.; Campbell RG. Risks and management of long-term corticosteroid use in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2018;26(1):1–7. https://doi.org/10.1097/moo.0000000000000421.; Han J, Gross G, Mannent L, Amin N, Cho S, Bachert C. Dupilumab Improves Sinus Opacification in All Sinuses in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Results From the SINUS-24 Phase 3 Study. J Allergy Clin Immunol. 2020;145(2):AB251. https://doi.org/10.1016/j.jaci.2019.12.109.; Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. https://doi.org/10.1111/all.13875.; Al-Ahmad M, Alsaleh S, Al-Reefy H, Abduwani JA, Nasr I, Al Abri R et al. Expert opinion on biological treatment of chronic rhinosinusitis with nasal polyps in the gulf region. J Asthma Allergy. 2022;15:1–12. https://doi.org/10.2147/jaa.s321017.

Availability: https://www.med-sovet.pro/jour/article/view/8830
https://doi.org/10.21518/ms2024-510

СОВРЕМЕННЫЕ СПОСОБЫ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ И ИХ КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ

Subject Terms: бронхиальная астма, эффективность лечения, клиническая картина, ингаляционные глюкокортикостероиды, ксантины, дети

СОВРЕМЕННЫЕ СПОСОБЫ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ И ИХ КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ

Subject Terms: бронхиальная астма, эффективность лечения, клиническая картина, ингаляционные глюкокортикостероиды, ксантины, дети

Сучасні підходи до вибору базисної терапії легкої персистуючої бронхіальної астми у дітей

Authors: Nedelska, S.M., Kuznietsova, O.D., Raskina, K.V.

Source: Zdorovʹe Rebenka, Vol 10, Iss 2.61, Pp 62-65 (2015)
CHILD`S HEALTH; № 2.61 (2015); 62-65
Здоровье ребенка-Zdorovʹe rebenka; № 2.61 (2015); 62-65
Здоров'я дитини-Zdorovʹe rebenka; № 2.61 (2015); 62-65

Subject Terms: children, бронхиальная астма, ингаляционные глюкокортикостероиды, антилейкотриеновые препараты, дети, leukotrien modifiers, бронхіальна астма, інгаляційні глюкокортикостероїди, антилейкотрієнові препарати, діти, bronchial asthma, inhaled glucocorticosteroids, Pediatrics, RJ1-570, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/02742bb584a04587aa62ffb85cbd424d
http://childshealth.zaslavsky.com.ua/article/download/75067/70513
http://childshealth.zaslavsky.com.ua/article/view/75067
http://childshealth.zaslavsky.com.ua/article/view/75067

Особенности обмена глюкозы у школьников с бронхиальной астмой, получающих базисную противовоспалительную терапию ингаляционными глюкокортикостероидами

Authors: Buryniuk-Glovyak, K.P., Koloskova, О.К.

Source: INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Том 16, № 1 (2020); 39-43
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 1 (2020); 39-43
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 1 (2020); 39-43

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, діти, бронхіальна астма, глюкоза, інгаляційні глюкокортикостероїди, children, bronchial asthma, glucose, inhalation glucocorticosteroids, дети, бронхиальная астма, ингаляционные глюкокортикостероиды, 3. Good health

File Description: application/pdf

Access URL: http://iej.zaslavsky.com.ua/article/download/199126/200682
http://iej.zaslavsky.com.ua/article/view/199126
http://iej.zaslavsky.com.ua/article/download/199126/200682
http://iej.zaslavsky.com.ua/article/view/199126

Bronchial asthma — a new paradigm in GINA clinical recommendations. Рart 1

Authors: Todoriko, L.D., Petrenko, V.I., Shevchenko, O.S., Semianiv, І.О., Makoyda, І.Ya., Ostrovskiy, M.M.

Source: Туберкулез, легочные болезни, ВИЧ-инфекция; № 1 (2020); 69-77
Туберкульоз, легеневі хвороби, ВІЛ-інфекція; № 1 (2020); 69-77
Tuberculosis, Lung Diseases, HIV Infection; № 1 (2020); 69-77

Subject Terms: бронхиальная астма, лечение, эпидемиология, бронхолитики, формотерол, ингаляционные глюкокортикостероиды, бронхіальна астма, лікування, епідеміологія, бронхолітики, інгаляційні глюкокортикостероїди, bronchial asthma, treatment, epidemiology, bronchodilators, formoterol, inhaled glucocorticosteroids, 3. Good health

File Description: application/pdf

Access URL: http://tubvil.com.ua/article/view/198955

Clinical efficacy of a triple combination of budesonide/ glycopyrronium bromide/formoterol in the treatment of chronic obstructive pulmonary disease ; Клиническая эффективность тройной комбинации будесонида/гликопиррония бромида/формотерола в лечении пациентов с хронической обструктивной болезнью легких

Authors: N. V. Trushenko, B. B. Lavginova, G. S. Nuralieva, S. N. Avdeev, Н. В. Трушенко, Б. Б. Лавгинова, Г. С. Нуралиева, С. Н. Авдеев

Source: Meditsinskiy sovet = Medical Council; № 20 (2023); 10-17 ; Медицинский Совет; № 20 (2023); 10-17 ; 2658-5790 ; 2079-701X

Subject Terms: длительнодействующие антагонисты мускариновых рецепторов, combination inhaler, inhaled corticosteroids, long-acting beta-agonists, long-acting anticholinergics, эозинофилия, комбинированные ингаляционные средства, ингаляционные глюкокортикостероиды, длительнодействующие бета2-агонисты

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7877/6992; Авдеев СН, Айсанов ЗР, Ардашева ТВ, Белевский АС, Демко ИВ, Зайцев АА и др. Хроническая обструктивная болезнь легких: клинические рекомендации. 2023. 100 с. Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf.; Авдеев СН, Айсанов ЗР, Архипов ВВ, Белевский АС, Визель АА, Демко ИВ и др. Назначение/отмена ингаляционных глюкокортикостероидов у больных хронической обструктивной болезнью легких как терапевтический континуум в реальной клинической практике. Пульмонология. 2023;33(1):109–118. https://doi.org/10.18093/0869-0189-202333-1-109-118.; Авдеев СН, Невзорова ВА, Куделя ЛМ, Кондрашова НМ, Суханова ГИ, Киняйкин МФ и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019;29(3):365–374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374.; Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of COPD. Expert Rev Clin Pharmacol. 2020;13(8):865–874. https://doi.org/10.1080/17512433.2020.1787830.; Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. https://doi.org/10.1016/S2213-2600(18)30327-8.; Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M et al. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509. https://doi.org/10.1016/j.rmed.2021.106509.; Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N et al. Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap. Int J Chron Obstruct Pulmon Dis. 2020;15:269–277. https://doi.org/10.2147/COPD.S231004.; Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-VerySevere COPD. N Engl J Med. 2020;383(1):35–48. https://doi.org/10.1056/NEJMoa1916046.; Singh D, Rabe KF, Martinez FJ, Krüll M, Jenkins M, Patel M, Dorinsky P. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022;197:106857. https://doi.org/10.1016/j.rmed.2022.106857.; Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/ Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021;203(5):553–564. https://doi.org/10.1164/rccm.202006-2618OC.; Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181–1184. https://doi.org/10.1016/j.jaci.2017.04.027.; Hasegawa K, Camargo CAJr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21(4):761–764. https://doi.org/10.1111/resp.12724.; Landis S, Suruki R, Maskell J, Bonar K, Hilton E, Compton C. Demographic and Clinical Characteristics of COPD Patients at Different Blood Eosinophil Levels in the UK Clinical Practice Research Datalink. COPD. 2018;15(2):177–184. https://doi.org/10.1080/15412555.2018.1441275.; Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565–572. https://doi.org/10.1378/chest.129.3.565.; Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5):1511–1517. https://doi.org/10.1164/ajrccm.158.5.9804028.; Park HY, Lee H, Koh WJ, Kim S, Jeong I, Koo HK et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;11:23–30. https://doi.org/10.2147/COPD.S94797.; Авдеев СН, Трушенко НВ, Мержоева ЗМ, Иванова МС, Кусраева ЭВ. Эозинофильное воспаление при хронической обструктивной болезни легких. Терапевтический архив. 2019;91(10):144–152. https://doi.org/10.26442/00403660.2019.10.000426.; Лещенко ИВ, Мещерякова АС. Современные возможности терапии ингаляционными глюкокортикостероидами пациентов с хронической обструктивной болезнью легких. Пульмонология. 2021;31(1):75–87. https://doi.org/10.18093/0869-0189-2021-31-1-75-87.; Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M et al. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–3073. https://doi.org/10.2147/COPD.S374670.; Muro S, Sugiura H, Darken P, Dorinsky P. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respir Res. 2021;22(1):187. https://doi.org/10.1186/s12931-021-01773-1.; Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM et al. Proportional classification of COPD phenotypes. Thorax. 2008;63(9):761–767. https://doi.org/10.1136/thx.2007.089193.; Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008;134(1):14–19. https://doi.org/10.1378/chest.07-2317.; Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12(1):127. https://doi.org/10.1186/1465-9921-12-127.; Park SY, Kim S, Kim JH, Kim SH, Lee T, Yoon SY et al. A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study. J Allergy Clin Immunol Pract. 2021;9(3):1304–1311. https://doi.org/10.1016/j.jaip.2020.09.066.; Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. https://doi.org/10.1056/NEJMoa1713901.; Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. https://doi.org/10.1016/S0140-6736(18)30206-X.; Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539–3547. https://doi.org/10.2147/COPD.S175047.; Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. https://doi.org/10.1136/thorax.57.10.847.; Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond Dual Bronchodilation – Triple Therapy, When and Why. Int J Chron Obstruct Pulmon Dis. 2022;17:165–180. https://doi.org/10.2147/COPD.S345263.

Availability: https://www.med-sovet.pro/jour/article/view/7877
https://doi.org/10.21518/ms2023-382

Retrospective evaluation of the effect of long-term use of inhalation glucocorticosteroids on physical development of children and adolescents with bronchial asthma

Authors: Burynyuk-Gloviak, Kristina, Ortemenka, Yevheniya

Source: ScienceRise: Medical Science; № 6 (33) (2019); 26-31
ScienceRise. Medical Science; № 6 (33) (2019); 26-31

Subject Terms: бронхиальная астма, дети, ингаляционные глюкокортикостероиды, физическое развитие, ретроспективный анализ, 2. Zero hunger, bronchial asthma, children, inhaled glucocorticosteroids, physical development, retrospective analysis, УДК: 616.248-053.2-085.357.032.23:612.6, бронхіальна астма, діти, інгаляційні глюкокортикостероїди, фізичний розвиток, ретроспективний аналіз, 3. Good health

File Description: application/pdf

Access URL: http://journals.uran.ua/sr_med/article/download/185635/186124
http://journals.uran.ua/sr_med/article/download/185635/186124
http://journals.uran.ua/sr_med/article/view/185635
https://www.neliti.com/publications/313645/retrospective-evaluation-of-the-effect-of-long-term-use-of-inhalation-glucocorti
http://journals.uran.ua/sr_med/article/view/185635

The Use of Inhaled Glucocorticosteroids (ICS) during the COVID-19 Pandemic ; Применение ингаляционных глюкокортикостероидов (ИГКС) во время пандемии COVID-19

Authors: A. A. Vizel, I. Yu. Vizel, M. K. Sagdieva, F. F. Yarkaeva, А. А. Визель, И. Ю. Визель, М. К. Сагьдиева, Ф. Ф. Яркаева

Source: Tuberculosis and Lung Diseases; Том 100, № 1 (2022); 7-18 ; Туберкулез и болезни легких; Том 100, № 1 (2022); 7-18 ; 2542-1506 ; 2075-1230

Subject Terms: безопасность, inhaled glucocorticosteroids, efficacy, safety, ингаляционные глюкокортикостероиды, эффективность

File Description: application/pdf

Relation: https://www.tibl-journal.com/jour/article/view/1601/1610; Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г., Беленков Ю. Н., Конради А. О., Лопатин Ю. М., Ребров А. П. и др. Анализ влияния препаратов базовой терапии, применявшихся для лечения сопутствующих заболеваний в период, предшествующий инфицированию, на риск летального исхода при новой коронавирусной инфекции. Данные международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2» (AКТИВ SARS-CoV-2) // Кардиология. ‒ 2021. – Т. 61, № 9. – С. 20-32. DOI:10.18087/cardio.2021.9.n1680.; Визель А., Визель И., Гизатуллина Э. Пневмония у больных ХОБЛ, получающих ингаляционные глюкокортикостероиды // Врач. ‒ 2017. ‒ № 1. – С. 17-23.; Визель А. А., Яушев М. Ф., Халфиев И. Н. Применение ингаляционного стероида ингакорта в комплексной терапии инфильтративного туберкулеза легких // Пульмонология. ‒ 2000. ‒ № 1. – С. 31-34.; Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (2019-nCoV). Версия 13.1 (09.11.2021): 209-2010.; Гудима Г. О., Хаитов Р. М., Кудлай Д. А., Хаитов М. Р. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции // Иммунология. ‒ 2021. ‒ Т. 42, № 3. ‒ С. 198-210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.; Фомина Д. С., Сердотецкова С. А., Иванова М. С., Белевский А. С., Княжеская Н. П., Лунцов А. В., Чернов А. А. Ведение пациентов с COVID-19 и бронхиальной астмой: обзор литературы и клинический опыт авторов // Практическая пульмонология. ‒ 2020. ‒ № 2. – С. 3-15.; Шпаков О. А. Ангиотензин-превращающий фермент 2-го типа как молекулярный посредник для инфицирования клетки вирусами SARS-CoV и SARS-CoV-2 // Российский физиологический журнал им. И. М. Сеченова. – 2020. – Т. 106, № 7. ‒ С. 795-810.; Agusti A., Torres F., Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 // Lancet Respir Med. – 2021. – Vol. 9, № 7. ‒ P. 682-683. doi:10.1016/S2213-2600(21)00171-5.; Al Sulaiman K., Aljuhani O., Al Aamer K., Al Shaya O., Al Shaya A., Alsaeedi A. S, Alhubaishi A., Altebainawi A. F., Al Harthi A., Albelwi S., Almutairi R., Alsubaie N., Alsallum A., Korayem G. B., Alfahed A., Kensara R., Altebainawi E. F., Alenezi R. S., Alsulaiman T., Al Enazi H., Vishwakarma R., Al Dabbagh T., Bakhsh U., Al Ghamdi G. The Role of inhaled corticosteroids (ICS) in critically ill patients with COVID-19: A multicenter, cohort study // J. Intens. Care Med. – 2021. ‒ Nov 10:8850666211053548. doi:10.1177/08850666211053548.; Butler C. C., Yu L. M., Dorward J., Gbinigie O., Hayward G., Saville B. R., Van Hecke O., Berry N., Detry M. A., Saunders C., Fitzgerald M., Harris V., Djukanovic R., Gadola S., Kirkpatrick J., de Lusignan S., Ogburn E., Evans P. H., Thomas N. P. B., Patel M. G., Hobbs F. D. R. PRINCIPLE Trial Collaborative Group. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial // Lancet Respir. Med. – 2021. ‒ Vol. 9, № 9. – P. 1010-1020. doi:10.1016/S2213-2600(21)00310-6.; Choi J. C., Jung S. Y., Yoon U. A., You S. H., Kim M. S., Baek M. S., Jung J. W., Kim W. Y. Inhaled corticosteroids and COVID-19 risk and mortality: A Nationwide Cohort Study // J. Clin. Med. – 2020. – Vol. 9, № 11. – P. 3406. doi:10.3390/jcm9113406.; Clemency B. M., Varughese R., Gonzalez-Rojas Y., Morse C. G., Phipatanakul W., Koster D. J., Blaiss M. S. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: A Randomized Clinical Trial // JAMA Intern. Med. ‒ 2021 Nov 22. doi:10.1001/jamainternmed.2021.6759. Epub ahead of print.; Daval M., Corré A., Palpacuer C., Housset J., Poillon G., Eliezer M., Verillaud B., Slama D., Ayache D., Herman P., Jourdaine C., Hervé C., El Bakkouri W., Salmon D., Hautefort C. Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial // Trials. – 2020. – Vol. 21, № 1. – P. 666. doi:10.1186/s13063-020-04585-8.; Ebell M. H. Inhaled budesonide reduces the risk of emergency department evaluation or hospitalization in early COVID-19 // Am. Fam. Physician. – 2021. – Vol. 104, № 2. – P. 207-208. PMID: 34383442.; Efe C., Lammert C., Taşçılar K., Dhanasekaran R., Ebik B., Higuera-de la Tijera F., Calışkan A. R., Peralta M., Gerussi A., Massoumi H., Catana A. M., Purnak T., Rigamonti C., Gomez Aldana A. J., Khakoo N., Nazal L., Frager S., Demir N., Irak K., Melekoğlu Ellik Z., Kacmaz H., Balaban Y., Atay K., Eren F., Alvares-da-Silva M. R., Cristoferi L., Urzua Á., Eşkazan T., Magro B., Snijders R., Barutçu S., Lytvyak E., Miranda Zazueta G., Demirezer Bolat A., Aydın M., Heurgue-Berlot A., De Martin E., Ekin N., Yıldırım S., Yavuz A., Bıyık M., Castro Narro G., Kıyıcı M., Akyıldız M., Kahramanoğlu-Aksoy E., Vincent M., Carr R. M., Günşar F., Cerda Reyes E., Harputoğlu M., Aloman C., Gatselis N. K., Üstündağ Y., Brahm J., Chris Escajadillo Vargas N., Güzelbulut F., Ruiz Garcia S., Aguirre J., Anders M., Ratusnu N., Hatemi I., Mendizabal M., Floreani A., Fagiuoli S., Silva M., Idilman R., Satapathy S. K., Silveira M., Drenth J. P. H., Dalekos G. N., Assis D. N., Björnsson E., Boyer J. L., Yoshida E. M., Invernizzi P., Levy C., Montano-Loza A. J., Schiano T. D., Ridruejo E., Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis // Liver Int. ‒ 2021. ‒ Nov 30. doi:10.1111/liv.15121. Epub ahead of print.; Farne H., Singanayagam A. Reply // J. Allergy Clin. Immunol. – 2021. – Vol. 147, № 3. – P. 1117-1118. doi:10.1016/j.jaci.2020.11.019.; Finney L. J., Glanville N., Farne H., Aniscenko J., Fenwick P., Kemp S. V., Trujillo-Torralbo M. B., Loo S. L., Calderazzo M. A., Wedzicha J. A., Mallia P., Bartlett N. W., Johnston S. L., Singanayagam A. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon // J. Allergy Clin. Immunol. – 2021. – Vol. 147, № 2. – P. 510-519.e5. doi:10.1016/j.jaci.2020.09.034. Epub 2020 Oct 15. PMID: 33068560; PMCID: PMC7558236.; Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Availaible from: www.ginasthma.org (Accessed: December, 2021).; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD. 2022 GOLD Reports. Available at: https://goldcopd.org/gold-reports/ (Accessed: December, 2021).; Halpin D. M. G., Singh D., Hadfield R. M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective // Eur. Respir. J. – 2020. – Vol. 55 (2001009). doi:10.1183/13993003.01009-2020.; Heinen N., Meister T. L., Klöhn M., Steinmann E., Todt D., Pfaender S. Antiviral effect of budesonide against SARS-CoV-2 // Viruses. – 2021. – Vol. 13, № 7. – P. 1411. doi:10.3390/v13071411.; Husby A., Pottegård A., Hviid A. Association between inhaled corticosteroid use and COVID-19 outcomes // Pharmacoepidemiol. Drug Saf. – 2021. – Vol. 30, № 11. – P. 1486-1492. doi:10.1002/pds.5345.; Iwabuchi K., Yoshie K., Kurakami Y., Takahashi K., Kato Y., Morishima T. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases // J. Infect. Chemother. – 2020. – Vol. 26, № 6. – P. 625-632. doi:10.1016/j.jiac.2020.04.007.; Jang J. G., Ahn J. H., Jin H. J. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease // Int. J. Chron. Obstruct. Pulmon. Dis. – 2021. Vol. 7, № 16. – P. 1265-1273. doi:10.2147/COPD.S306916.; Jordan A., Sivapalan P., Jensen J. U. Does inhaled corticosteroid use affect the risk of COVID-19-related death? // Breathe (Sheff). ‒ 2021. – Vol. 17, № 1. – P. 200275. doi:10.1183/20734735.0275-2020.; Karampela I., Vallianou N. G., Tsilingiris D., Christodoulatos G. S., Muscogiuri G., Barrea L., Vitale G., Dalamaga M. Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence // Panminerva Med. – 2021. ‒ Dec 3. doi:10.23736/S0031-0808.21.04595-X. Epub ahead of print.; Kareemi H., Rosenberg H., Yadav K. Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19? // CJEM. – 2021. – Vol. 23, № 5. ‒ P. 611-612. doi:10.1007/s43678-021-00154-3.; Kluge S., Nitschmann S., Scherer M. Inhalatives budesonid zur therapie bei COVID-19 [Inhaled budesonide in the treatment of COVID-19] // Internist (Berl). – 2021. ‒ Vol. 62, № 8. – P. 887-889. German. doi:10.1007/s00108-021-01071-4.; Lee S. C., Son K. J., Han C. H., Jung J. Y., Park S. C. Association between inhaled corticosteroid use and SARS-CoV-2 infection: A nationwide population-based study in South Korea // Tuberc. Respir. Dis. (Seoul). ‒ 2021. ‒ Nov 30. doi:10.4046/trd.2021.0102. Epub ahead of print.; Lipworth B., Chan R., Kuo C. Inhaled corticosteroids and angiotensinconverting enzyme-2 in COPD // J. Allergy Clin. Immunol. ‒ 2021. – Vol. 147, № 3. – P. 1117-1118. doi:10.1016/j.jaci.2020.11.019.; Mahase E. COVID-19: Increased demand for steroid inhalers causes "distressing" shortages. // BMJ. ‒ 2020. ‒ № 369. – P.m1393. doi:10.1136/bmj.m1393.; Milne S., Li X., Yang C. X., Leitao Filho F. S., Hernández Cordero A. I., Yang C. W. T., Shaipanich T., van Eeden S. F., Leung J. M., Lam S., Sin D. D. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: № 1. – P. 2100130. doi:10.1183/13993003.00130-2021.; Nicolau D. V., Bafadhel M. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19? // Lancet Respir. Med. ‒ 2020. – Vol. 8, № 9. – P. 846-847. doi:10.1016/S2213-2600(20)30314-3.; Patel S. K., Kumar R., Rana J., Agrawal A., Singh A., Kumar A. Budesonide: A promising candidate therapeutic for early COVID-19 // Ann. Med. Surg. (Lond). – 2021. ‒ № 68. – P. 102605. doi:10.1016/j.amsu.2021.102605.; Peters M. C., Sajuthi S., Deford P., Christenson S., Rios C. L., Montgomery M. T., Woodruff P. G., Mauger D. T., Erzurum S. C., Johansson M. W., Denlinger L. C., Jarjour N. N., Castro M., Hastie A. T., Moore W., Ortega V. E., Bleecker E. R., Wenzel S. E., Israel E., Levy B. D., Seibold M. A., Fahy J. V. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids // Am. J. Respir. Crit. Care Med. – 2020. – Vol. 202, № 1. – P. 83-90. doi:10.1164/rccm.202003-0821OC.; PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial // Lancet. 2021. ‒ Mar 20. ‒ № 397 (10279). ‒ Р. 1063-1074. doi:10.1016/S0140-6736(21)00461-X.; Ramakrishnan S., Nicolau D. V. Jr., Langford B., Mahdi M., Jeffers H., Mwasuku C., Krassowska K., Fox R., Binnian I., Glover V., Bright S., Butler C., Cane J. L., Halner A., Matthews P. C., Donnelly L. E., Simpson J. L., Baker J. R., Fadai N. T., Peterson S., Bengtsson T., Barnes P. J., Russell R. E. K., Bafadhel M. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial // Lancet Respir. Med. – 2021. – Vol. 9, № 7. – P. 763-772. doi:10.1016/S2213-2600(21)00160-0.; Rathi S., Ish P., Kalantri A., Kalantri S. Inhaled budesonide for mild COVID-19. Is there more to it than just airways? // Adv. Respir. Med. – 2021. – Vol. 89, № 5. – P. 552-553. doi:10.5603/ARM.a2021.0082.; RECOVERY Collaborative Group, Horby P., Lim W. S., Emberson J. R., Mafham M., Bell J. L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L. C., Faust S. N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J. K., Haynes R., Landray M. J. Dexamethasone in hospitalized patients with COVID-19 // N. Engl. J. Med. – 2021. ‒ Vol. 25, № 384 (8). ‒ P. 693-704. doi:10.1056/NEJMoa2021436.; San-Juan R., Fernández-Ruiz M., López-Medrano F., Aguado J. M. Inhaled budesonide for early treatment of COVID-19 // Lancet Respir. Med. – 2021. – Vol. 9, № 7. – P. e58. doi:10.1016/S2213-2600(21)00211-3.; Schultze A., Walker A. J., MacKenna B., Morton C. E., Bhaskaran K., Brown J. P., Rentsch C. T., Williamson E., Drysdale H., Croker R., Bacon S., Hulme W., Bates C., Curtis H. J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H. I., Tomlinson L., Mathur R., Wing K., Wong A. Y. S., Forbes H., Parry J., Hester F., Harper S., Evans S. J. W., Quint J., Smeeth L., Douglas I. J., Goldacre B. OpenSAFELY Collaborative. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform // Lancet Respir. Med. – 2020. – Vol. 8, № 11. – P. 1106-1120. doi:10.1016/S2213-2600(20)30415-X.; Schultze A., Walker A. J., MacKenna B., Morton C. E., Bhaskaran K., Brown J. P., Rentsch C. T., Williamson E., Drysdale H., Croker R., Bacon S., Hulme W., Bates C., Curtis H. J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H. I., Tomlinson L., Mathur R., Wing K., Wong A. Y. S., Forbes H., Parry J., Hester F., Harper S., Evans S. J. W., Quint J., Smeeth L., Douglas I. J., Goldacre B. OpenSAFELY Collaborative. Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis // MedRxiv. ‒ 2020; published online June 20. https://www.medrxiv.org/content/10.1101/2020.06.19.20135491v1 (preprint).; Sen P., Majumdar U., Zein J., Hatipoğlu U., Attaway A. H. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry // PLoS One. – 2021. – Vol. 16, № 6. – P. e0252576. doi:10.1371/journal.pone.0252576.; Starshinova A., Malkova A., Yablonskiy P., Shoenfeld Y., Zinchenko U., Dovgalyk I., Kudlay D., Glushkova A. Efficacy of different types of therapy for COVID-19: a comprehensive review // Life. ‒2021. ‒ Vol. 11, № 8. ‒ Р. 753.; Wark P. A. B., Pathinayake P. S., Eapen M. S., Sohal S. S. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights // Eur. Respir. J. 2021. – Vol. 58, № 2. – P. 100920. doi:10.1183/13993003.00920-2021.; Xiong R., Zhao Z., Lu H., Ma Y., Zeng H., Chen Y. Asthma patients benefit more than chronic obstructive pulmonary disease patients in the coronavirus disease 2019 рandemic // Front. Med (Lausanne). ‒ 2021. ‒ № 8. – P. 709006. doi:10.3389/fmed.2021.709006.; Yamaya M., Nishimura H., Deng X., Sugawara M., Watanabe O., Nomura K., Shimotai Y., Momma H., Ichinose M., Kawase T. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells // Respir. Investig. – 2020. – Vol. 58, № 3. – P. 155-168. doi:10.1016/j.resinv.2019.12.005.; Yu L. M., Bafadhel M., Dorward J., Hayward G., Saville B. R., Gbinigie O., Van Hecke O., Ogburn E., Evans P. H., Thomas N. P. B., Patel M. G., Richards D., Berry N., Detry M. A., Saunders C., Fitzgerald M., Harris V., Shanyinde M., de Lusignan S., Andersson M. I., Barnes P. J., Russell R. E. K., Nicolau D. V. Jr., Ramakrishnan S., Hobbs F. D. R., Butler C. C. PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial // Lancet. – 2021. – Vol. 398, № 10303. – P. 843-855. doi:10.1016/S0140-6736(21)01744-X.

Availability: https://www.tibl-journal.com/jour/article/view/1601
https://doi.org/10.21292/2075-1230-2022-100-1-7-18

Federal guidelines on diagnosis and treatment of bronchial asthma ; Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению

Authors: A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, O. S. Vasil’eva, N. A. Geppe, G. L. Ignatova, N. P. Knyazheskaya, A. B. Malakhov, N. I. Meshcheryakova, N. M. Nenasheva, R. S. Fassakhov, R. M. Khaitov, N. I. Il’ina, O. M. Kurbacheva, N. G. Astafieva, I. V. Demko, D. S. Fomina, L. S. Namazova-Baranova, A. A. Baranov, E. A. Vishneva, G. A. Novik, А. Г. Чучалин, С. Н. Авдеев, З. Р. Айсанов, А. С. Белевский, О. С. Васильева, Н. А. Геппе, Г. Л. Игнатова, Н. П. Княжеская, А. Б. Малахов, Н. Н. Мещерякова, Н. М. Ненашева, Р. С. Фассахов, Р. М. Хаитов, Н. И. Ильина, О. М. Курбачева, Н. Г. Астафьева, И. В. Демко, Д. С. Фомина, Л. С. Намазова-Баранова, А. А. Баранов, Е. А. Вишнева, Г. А. Новик

Source: PULMONOLOGIYA; Том 32, № 3 (2022): Спецвыпуск; 393-447 ; Пульмонология; Том 32, № 3 (2022): Спецвыпуск; 393-447 ; 2541-9617 ; 0869-0189

Subject Terms: биологическая терапия, recommendations, bronchodilators, inhaled glucocorticosteroids, biological therapy, рекомендации, бронходилататоры, ингаляционные глюкокортикостероиды

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4109/3415; Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2018. Available at: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf; Chuchalin A.G., Khaltaev N., Аntonov N.S. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963–974. DOI:10.2147/COPD.S67283.; Российское респираторное общество. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 4-е изд. М.: 2012.; Centers for Disease Control and Prevention. Most recent asthma data. Available at: http://www.cdc.gov/asthma/most_recent_data.htm; Krahn M.D., Berka C., Langlois P., Detsky A.S. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996; 154 (6): 821–831.; Weber E.J., Silverman R.A., Callaham M.L. et al. A prospective multicenter study factors associated with hospital admission among adults with acute asthma. Am. J. Med. 2002; 113 (5): 371–378. DOI:10.1016/s0002-9343(02)01242-1.; Braman S.S., Kaermmerhen J.T. Intensive care of status asthmaticus: A 10-year experience. JAMA. 1990; 264 (3): 366–368. DOI:10.1001/jama.1990.03450030090038.; Salmeron S., Liard R., Elkharrat D. et al. Asthma severity adequacy of management in accident and emergency departments in France: a prospective study. Lancet. 2001; 358 (9282): 629–635. DOI:10.1016/s0140-6736(01)05779-8.; Krishnan V., Diette G.B., Rand C.S. et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am. J. Respir. Crit. Care Med. 2006; 174 (6): 633–638. DOI:10.1164/rccm.200601-007OC.; Ненашева Н.М. Клинические фенотипы атопической бронхиальной астмы: диагностика и лечение. Saarbrucken: Palmarium Academic Publishing; 2012.; Moore W.C., Meyers D.A., Wenzel S.E. et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am. J. Respir. Crit. Care Med. 2010; 181 (4): 315–323. DOI:10.1164/rccm.200906-0896OC.; Pearce N., Pekkanen J., Beasley R. How much asthma is really attributable to atopy? Thorax. 1999; 54 (3): 268–272. DOI:10.1136/thx.54.3.268.; Mellis C. Respiratory noises: how useful are they clinically? Pediatr. Clin. North Am. 2009; 56 (1): 1–17. DOI:10.1016/j.pcl.2008.10.003.; Cano Garcinuno A., Mora Gandarillas I., SLAM Study Group. Early patterns of wheezing in asthmatic and nonasthmatic children. Eur. Respir. J. 2013; 42 (4): 1020–1028. DOI:10.1183/09031936.00148712.; Just J., Saint-Pierre P., Gouvis-Echraghi R. et al. Wheeze phenotypes in young children have different courses during the preschool period. Ann. Allergy Asthma Immunol. 2013; 111 (4): 256–261. DOI:10.1016/j.anai.2013.07.002.; O’Byrne P.M., Reddel H.K., Eriksson G. et al. Measuring asthma control: a comparison of three classification systems. Eur. Respir. J. 2010; 36 (2): 269–276. DOI:10.1183/09031936.00124009.; Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI:10.4104/pcrj.2009.00010.; Juniper E.F., Svensson K., Mörk A.C., Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med. 2005; 99 (5): 553–558. DOI:10.1016/j.rmed.2004.10.008.; Kerkhof M., Tran T.N., van den Berge M. et al. Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS One. 2018; 13 (7): e0201143. DOI:10.1371/journal.pone.0201143.; Price D.B., Rigazio A., Campbell J.D. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 2015; 3 (11): 849–858. DOI:10.1016/S2213-2600(15)00367-7.; Albers F.C., Licskai C., Chanez P. et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir. Med. 2019; 159: 105806. DOI:10.1016/j.rmed.2019.105806.; Bush A. Management of asthma in children. Minerva Pediatr. 2018; 70 (5): 444–457. DOI:10.23736/S0026-4946.18.05351-3.; Rath N., Raje N., Rosenwasser L. Immunoglobulin E as a biomarker in asthma. Immunol. Allergy Clin. North Am. 2018; 38 (4): 587–597. DOI:10.1016/j.iac.2018.06.007.; Ahlstedt S., Murray C.S. In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice. Prim. Care Respir. J. 2006; 15 (4): 228–236. DOI:10.1016/j.pcrj.2006.05.004.; Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338. DOI:10.1183/09031936.05.00034805.; Levy M.L., Quanjer P.H., Booker R. et al. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations. Prim. Care Respir. J. 2009; 18 (3): 130–147. DOI:10.4104/pcrj.2009.00054.; Российское респираторное общество. Методические рекомендации по использованию метода спирометрии. М.; 2016. Доступно на: http://www.spulmo.ru; Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26 (5): 948–968. DOI:10.1183/09031936.05.00035205.; Tan W.C., Vollmer W.M., Lamprecht B. et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012; 67 (8): 718–726. DOI:10.1136/thoraxjnl-2011-201445.; Crapo R.O., Casaburi R., Coates A.L. et al. Guidelines for methacholine and exercise challenge testing-1999. Am. J. Respir. Crit. Care Med. 2000; 161 (1): 309–329. DOI:10.1164/ajrccm.161.1.ats11-99.; Swartz E., Lang D. When should a methacholine challenge be ordered for a patient with suspected asthma? Cleve Clin. J. Med. 2008; 75 (1): 37–40. DOI:10.3949/ccjm.75.1.37.; Parsons J.P., Hallstrand T.S., Mastronarde J.G. et al. An official American Thoracic Society clinical practice guideline: exerciseinduced bronchoconstriction. Am. J. Respir. Crit. Care Med. 2013; 187 (9): 1016–1027. DOI:10.1164/rccm.201303-0437ST.; Reddel H.K., Taylor D.R., Bateman E.D. et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180 (1): 59–99. DOI:10.1164/rccm.200801-060ST.; Brouwer A.F., Brand P.L. Asthma education and monitoring: what has been shown to work. Paediatr. Respir. Rev. 2008; 9 (3): 193–199. DOI:10.1016/j.prrv.2008.03.001.; Beydon N., Davis S.D., Lombardi E. et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am. J. Respir. Crit. Care Med. 2007; 175 (12): 1304–1345. DOI:10.1164/rccm.200605-642ST.; Graham B.L., Steenbruggen I., Miller M.R. et al. Standardization of spirometry 2019 update: An official American Thoracic Society and European Respiratory Society technical statement. Am. J. Respir. Crit. Care Med. 2019; 200 (8): e70–88. DOI:10.1164/rccm.201908-1590ST.; American Thoracic Society, European Respiratory Society. ATS/ ERS Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005; 171 (8): 912–930. DOI:10.1164/rccm.200406-710ST.; Schleich F.N., Manise M., Sele J. et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm. Med. 2013; 13: 11. DOI:10.1186/1471-2466-13-11.; Dweik R.A., Boggs P.B., Erzurum S.C. et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 2011; 184 (5): 602–615. DOI:10.1164/rccm.9120-11ST.; Malo J.L., Côte J., Cartier A. et al. How many times per day should peak expiratory flow rates be assessed when investigating occupational asthma? Thorax. 1993; 48 (12): 1211–1217. DOI:10.1136/thx.48.12.1211.; Baur X., Huber H., Degens P.O. et al. Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. Am. J. Ind. Med. 1998; 33 (2): 114–122. DOI: : https://doi.org/10.1002/(sici)1097-0274(199802)33:23.0.co;2-y; Fishwick D., Barber C.M., Bradshaw L.M. et al. Standards of care for occupational asthma. Thorax. 2008; 63 (3): 240–250. DOI:10.1136/thx.2007.083444.; Mapp C.E., Saetta M., Maestrelli P., Fabbri L. Occupational asthma. In: Mapp C.E., ed. Occupational Lung Disorders. European Respiratory Monograph. Sheffield: ERS; 1999; 4 (Monogr. 11): 255–285.; Bousquet J., Heinzerling L., Bachert C. et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012; 67 (1): 18–24. DOI:10.1111/j.1398-9995.2011.02728.x.; Ait-Khaled N., Enarson D.A., Chiang C.Y. et al. Management of asthma: a guide to the essentials of good clinical practice. Paris: International Union Against Tuberculosis and Lung Disease; 2008.; Papadopoulos N.G., Arakawa H., Carlsen K.H. et al. International consensus on (ICON) pediatric asthma. Allergy. 2012; 67 (8): 976– 977. DOI:10.1111/j.1398-9995.2012.02865.x.; Намазова-Баранова Л.С., Баранов А.А., Хаитов Р.М., ред. Аллергология и иммунология. М.: Педиатръ; 2020.; Doherty G., Bush A. Diagnosing respiratory problems in young children. Practitioner. 2007; 251 (1697): 20, 22–25.; Gibson P.G., Powell H., Coughlan J. et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst. Rev. 2003: (1): CD001117. DOI:10.1002/14651858.CD001117.; Fishwick D., D’Souza W., Beasley R. The asthma self-management plan system of care: What does it mean, how is it done, does it work, what models are available, what do patients want and who needs it? Patient Educ. Couns. 1997; 32 (Suppl. 1): S21–33. DOI:10.1016/s0738-3991(97)00093-1.; Ramnath V.R., Clark S., Camargo C.A. Jr. Multicenter study of clinical features of sudden-onset versus slower-onset asthma exacerbations requiring hospitalization. Respir. Care. 2007; 52 (8): 1013–1020. Available at: http://rc.rcjournal.com/content/52/8/1013; Geelhoed G.C., Landau L.I., Le Souef P.N. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann. Emerg. Med. 1994; 23 (6): 1236–1241. DOI:10.1016/s0196-0644(94)70347-7.; Atta J.A., Nunes M.P.T., Fonseca-Guedes C.H.F. et al. Patient and physician evaluation of the severity of acute asthma exacerbations. Braz. J. Med. Biol. Res. 2004; 37 (9): 1321–1330. DOI:10.1590/s0100-879x2004000900006.; Nowak R.M., Tomlanovich M.C., Sarkar D.D. et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA. 1983; 249 (15): 2043–2046. DOI:10.1001/jama.1983.03330390047030.; White C.S., Cole R.P., Lubetsky H.W., Austin J.H. Acute asthma: Admission chest radiography in hospitalized adult patients. Chest. 1991; 100 (1): 14–16. DOI:10.1378/chest.100.1.14.; Taylor D.R., Bateman E.D., Boulet L.P. et al. A new perspective on concepts of asthma severity and control. Eur. Respir. J. 2008; 32 (3): 545–554. DOI:10.1183/09031936.00155307.; O’Byrne P.M., FitzGerald M., Bateman E.D. et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N. Engl. J. Med. 2018; 378 (20): 1865–1876. DOI:10.1056/NEJMoa1715274.; Bateman E.D., Reddel H.K., O’Byrne P.M. et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N. Engl. J. Med. 2018; 378 (20): 1877–1887. DOI:10.1056/NEJMoa1715275.; Papi A., Canonica G.W., Maestrelli P. et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N. Engl. J. Med. 2007; 356 (20): 2040–2052. DOI:10.1056/NEJMoa063861.; Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Принципы выбора терапии для больных легкой бронхиальной астмой: Согласованные рекомендации РААКИ и РРО. Практическая пульмонология. 2017; (1): 82–92. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_1_2017_82.pdf.; Pauwels R.A., Pedersen S., Busse W.W. et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003; 361 (9363): 1071–1076. DOI:10.1016/S0140-6736(03)12891-7.; O’Byrne P.M., Barnes P.J., Rodriguez-Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164 (8, Pt 1): 1392–1397. DOI:10.1164/ajrccm.164.8.2104102.; Adams N.P., Bestall J.B., Malouf R. et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst. Rev. 2005 (1): CD002738. DOI:10.1002/14651858.CD002738.pub2.; Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin. Exp. Allergy. 2001; 31 (4): 616–624. DOI:10.1046/j.1365-2222.2001.01088.x.; Philip G., Nayak A.S., Berger W.E. et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 2004; 20 (10): 1549–1558. DOI:10.1185/030079904x3348.; Guevara J.P., Ducharme F.M., Keren R. et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst. Rev. 2006; 2006 (2): CD003558. DOI:10.1002/14651858.CD003558.pub2.; Bisgaard H., Zielen S., Garcia-Garcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (4): 315–322. DOI:10.1164/rccm.200407-894OC.; Matsuse H., Tsuchida T., Fukahori S. et al. Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations. Allergy Rhinol. (Providence). 2013; 4 (3): e127–131. DOI:10.2500/ar.2013.4.0062.; Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2010; (5): CD005535. DOI:10.1002/14651858.CD005535.pub2.; Woodcock A., Vestbo J., Bakerly N.D.et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017; 390 (10109): 2247–2255. DOI:10.1016/S0140-6736(17)32397-8.; Cates C.J., Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013; (4): CD007313 DOI:10.1002/14651858.CD007313.pub3.; Papi A., Corradi M., Pigeon-Francisco C. et al. Beclometasone– formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir. Med. 2013; 1 (1): 23–31. DOI:10.1016/S2213-2600(13)70012-2.; Patel M., Pilcher J., Pritchard A. et al. Efficacy and safety of maintenance and reliever combination budesonide/formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir. Med. 2013; 1 (1): 32–42. DOI:10.1016/S2213-2600(13)70007-9.; Bateman E.D., Harrison T.W., Quirce S. et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir. Res. 2011; 12 (1): 38. DOI:10.1186/1465-9921-12-38.; Ni Chroinin M., Lasserson T.J., Greenstone I., Ducharme F.M. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst. Rev. 2009; 8 (3): CD007949. DOI:10.1002/14651858.CD007949.; Vaessen-Verberne A.A., van den Berg N.J., van Nierop J.C. et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am. J. Respir. Crit. Care Med. 2010; 182 (10): 1221–1227. DOI:10.1164/rccm.201002-0193OC.; Peters S.P., Kunselman S.J., Icitovic N. et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010; 363 (18): 1715–1726. DOI:10.1056/NEJMoa1008770.; Bateman E.D., Kornmann O., Schmidt P. et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011; 128 (2): 315–322. DOI:10.1016/j.jaci.2011.06.004.; Kerstjens H.A., Casale T.B., Bleeker E.R. et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir. Med. 2015; 3 (5): 367–376. DOI:10.1016/S2213-2600(15)00031-4.; Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2016; (1): CD011721. DOI:10.1002/14651858.CD011721.pub2.; Rodrigo G.J., Neffen H. Efficacy and safety of tiotropium in schoolage children with moderate-to-severe symptomatic asthma: a systematic review. Pediatr. Allergy Immunol. 2017; 28 (6): 573–578. DOI:10.1111/pai.12759.; Rodrigo G.J., Castro-Rodriguez J.A. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2015; 147 (2): 388–396. DOI:10.1378/chest.14-1698.; Kerstjens H.A., Disse B., Schröder-Babo W. et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2011; 128 (2): 308–314. DOI:10.1016/j.jaci.2011.04.039.; Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198–1207. DOI:10.1056/NEJMoa1208606.; FitzGerald M., Moroni-Zentgraf P., Engel M. et al. Once-daily tiotropium Respimat® add-on therapy improves symptom control across severtiies of symptomatic asthma, independent of allergic status. Poster 64426 presented at the American Thoracic Society 2015 International Conference. Denver, USA; 2015.; Lee L.A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 2021; 9 (1): 69–84. DOI:10.1016/S2213-2600(20)30389-1.; O’Byrne P.M., Naya I.P., Kallen A. et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008; 134 (6): 1192–1199. DOI:10.1378/chest.08-1018.; Price D.B., Hernandez D., Magyar P. et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003; 58 (3): 211–216. DOI:10.1136/thorax.58.3.211.; Vaquerizo M.J., Casan P., Castillo J. et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58 (3): 204–210. DOI:10.1136/thorax.58.3.204.; Tamaoki J., Kondo M., Sakai N. et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155 (4): 1235–1240. DOI:10.1164/ajrccm.155.4.9105060.; Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab vs placebo as addon therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011; 139 (1): 28–35. DOI:10.1378/chest.10-1194.; Normansell R., Walker S., Milan S.J. et al. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. 2014; (1): CD003559. DOI:10.1002/14651858.CD003559.pub4.; Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI:10.1016/S2213-2600(15)00042-9.; Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI:10.1016/S0140-6736(12)60988-X.; Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1198–1207. DOI:10.1056/NEJMoa1403290.; Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1189–1197. DOI:10.1056/NEJMoa1403291.; FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI:10.1016/S0140-6736(16)31322-8.; Bleecker E.R, FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2 -agonists (SIROCCO): a randomized, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI:10.1016/S0140-6736(16)31324-1.; Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 2018; 378 (26): 2486–2496. DOI:10.1056/NEJMoa1804092.; Rabe K.F., Nair P., Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 2018; 378 (26): 2475–2485. DOI:10.1056/NEJMoa1804093.; Zayed Y., Kheiri B., Banifadel M. et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J. Asthma. 2018; 56 (10): 1110–1119. DOI:10.1080/02770903.2018.1520865.; Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. A GINA Pocket Guide for Health Professionals. 2019. Available at: www.ginasthma.org; Chung K.F., Wenzel S.E., Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014; 43 (2): 343–373. DOI:10.1183/09031936.00202013.; Rivington R.N., Boulet L.P., Côté J. et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on highdose inhaled steroids. Am. J. Respir. Crit. Care Med. 1995; 151 (2, Pt 1): 325–332. DOI:10.1164/ajrccm.151.2.7842186.; Vogelberg C., Moroni-Zentgraf P., Lronaviciute-Klimantaviciene M. et al. A randomized dose-ranging study of tiotropium Respimat in children with symptomatic asthma despite inhaled corticosteroids. Repir. Res. 2015; 16 (1): 20. DOI:10.1186/s12931-015-0175-9.; Guo J.J., Tsai K., Kelton C.M.L. et al. Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study. Ann. Allergy Asthma Immunol. 2011; 106 (3): 214–222. DOI:10.1016/j.anai.2010.12.008.; Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938. DOI:10.1016/j.rmed.2011.01.005.; Fink J.B., Rubin B.K. Problems with inhaler use: a call for improved clinician and patient education. Respir. Care. 2005; 50 (10): 1360–1375. Available at: http://rc.rcjournal.com/content/50/10/1360; Basheti I.A., Reddel H.K., Armour C.L., Bosnic-Anticevich S.Z. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J. Allergy Clin. Immunol. 2007; 119 (6): 1537–1538. DOI:10.1016/j.jaci.2007.02.037.; Honkoop P.J., Loymans R.J.B., Termeer E.H. et al. Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment. BMC Pulm. Med. 2011; 11: 53. DOI:10.1186/1471-2466-11-53.; Eber E., Midulla F., eds. Paediatric Respiratory Medicine. ERS Handbook. 1st edn. Charlesworth Press; 2013. Available at: https://dl.uswr.ac.ir/bitstream/Hannan/140448/1/9781849840385.pdf; Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2010; (8): CD001186. DOI:10.1002/14651858.CD001186.pub2.; Tao L., Shi B., Shi G., Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Clin. Respir. J. 2014; 8 (2): 192–205. DOI:10.1111/crj.12058.; Virchow J.C., Backer V., Kuna P. et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016; 315 (16): 1715–1725. DOI:10.1001/jama.2016.3964.; Mosbech H., Deckelmann R., de Blay F. et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2014; 134 (3): 568–575.e7. DOI:10.1016/j.jaci.2014.03.019.; Hondras M.A., Linde K., Jones A.P. Manual therapy for asthma. Cochrane Database Syst. Rev. 2005; (2): CD001002. DOI:10.1002/14651858.CD001002.pub2.; Cooper S., Oborne J., Newton S. et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomized controlled trial. Thorax. 2003; 58 (8): 674–679. DOI:10.1136/thorax.58.8.674.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Пути улучшения диагностики и лечения больных бронхиальной астмой врачами первичного звена. Пульмонология. 2019; 29 (4): 457– 467. DOI:10.18093/0869-0189-2019-29-4-457-467.; Perrin K., Wijesinghe M., Healy B., et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax. 2011; 66 (11): 937–941. DOI:10.1136/thx.2010.155259.; Edmonds M.L., Milan S.J., Camargo C.A. et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst. Rev. 2012; (12): CD002308. DOI:10.1002/14651858.CD002308.pub2.; Cates C.J., Welsh E.J., Rowe B.H. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst. Rev. 2013; (9): CD000052. DOI:10.1002/14651858.CD000052.pub3.; Rodrigo G.J., Rodrigo C., Hall J.B. Acute asthma in adults: a review. Chest. 2004; 125 (3): 1081–1102. DOI:10.1378/chest.125.3.1081.; Hasegawa T., Ishihara K., Takakura S. et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern. Med. 2000; 39 (10): 794–797. DOI:10.2169/internalmedicine.39.794.; Jones A.M., Munavvar M., Vail A. et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir. Med. 2002; 96 (11): 950–954. DOI:10.1053/rmed.2002.1369.; Авдеев С.Н., Жестков А.В., Лещенко И.В. и др. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование. Пульмонология. 2006; (4): 58–67. Доступно на: https://journal.pulmonology.ru/pulm/article/view/1476.; Овчаренко С.И., Переделъская О.А., Морозова Н.В., Маколкин В.И. Небулайзерная терапия бронхолитиками и суспензией Пульмикорта® в лечении тяжелых обострений бронхиальной астмы. Пульмонология. 2003; (6): 75–83. Доступно на: https://journal.pulmonology.ru/pulm/article/view/2597/2029.; Ediger D., Coşkun F., Kunt Uzaskan E. et al. Clinical effectiveness of nebulized budesonide in the treatment of acute asthma attacks. Tuberkuloz ve Toraks Dergisi. 2006; 54 (2): 128–136. Available at: http://www.tuberktoraks.org/managete/fu_folder/2006-02/2006-54-2-128-136.pdf; Higenbottam T., Britton J., Lawrence D. et al. Comparison of nebulised Budesonide and Prednisolone in severe asthma exacerbation in adults. BioDrugs. 2000; 14 (4): 247–254. DOI:10.2165/00063030-200014040-00004.; Chien J.W., Ciufo R., Novak R. et al. Uncontrolled oxygen administration and respiratory failure in acute asthma. Chest. 2000; 117 (3): 728–733. DOI:10.1378/chest.117.3.728.; Rodrigo G.J., Rodriquez Verde M., Peregalli V., Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest. 2003; 124 (4): 1312–1317. DOI:10.1378/chest.124.4.1312.; Rodrigo G.J., Castro-Rodriguez J.A. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005; 60 (9): 740–746. DOI:10.1136/thx.2005.040444.; Camargo C.A. Jr, Spooner C.H., Rowe B.H. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst. Rev. 2003; (4): CD001115. DOI:10.1002/14651858.CD001115.; Nair P., Milan S.J., Rowe B.H. Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma. Cochrane Database Syst. Rev. 2012; (12): CD002742. DOI:10.1002/14651858.CD002742.pub2.; Ayres J.G. Classification and management of brittle asthma. Br. J. Hosp. Med. 1997; 57 (8): 387–389.; Kolbe J., Fergusson W., Garrett J. Rapid onset asthma: a severe but uncommon manifestation. Thorax. 1998; 53 (4): 241–247. DOI:10.1136/thx.53.4.241.; Rowe B.H., Bretzlaff J.A., Bourdon C. et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst. Rev. 2000; (2): CD001490. DOI:10.1002/14651858.CD001490.; FitzGerald J.M. Magnesium sulfate is effective for severe acute asthma treated in the emergency department. West J. Med. 2000; 172 (2): 96. DOI:10.1136/ewjm.172.2.96-a.; Gallegos-Solorzano M.C., Perez-Padilla R., Hernandez-Zenteno R.J. Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. Pulm. Pharmacol. Ther. 2010; 23 (5): 432–437. DOI:10.1016/j.pupt.2010.04.006.; Rodrigo G.J., Castro-Rodriguez J.A. Heliox-driven beta2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann. Allergy Asthma Immunol. 2014; 112 (1): 29–34. DOI:10.1016/j.anai.2013.09.024.; Pozin N., Montesantos S., Katz I. et al. Calculated ventilation and effort distribution as a measure of respiratory disease and Heliox effectiveness. J. Biomech. 2017; 60: 100–109. DOI:10.1016/j.jbiomech.2017.06.009.; Silverman R.A., Nowak R.M., Korenblat P.E. et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, doubleblind, multicenter trial. Chest. 2004; 126 (5): 1480–1489. DOI:10.1378/chest.126.5.1480.; Ramsay C.F., Pearson D., Mildenhall S., Wilson A.M. Oral montelukast in acute asthma exacerbations: a randomised, doubleblind, placebo-controlled trial. Thorax. 2011; 66 (1): 7–11. DOI:10.1136/thx.2010.135038.; Gupta D., Hath A., Agarwal R., Behera D. A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma. Respir. Care. 2010; 55 (5): 536–543. Available at: http://rc.rcjournal.com/content/55/5/536; Georgopoulos D., Burchardi H. Ventilation strategies in adult patients with status asthmaticus. Eur. Respir. Mon. 1998; 3: 45–83.; Авдеев С.Н. Респираторная поддержка при астматическом статусе. В кн.: Чучалин А.Г., ред. Бронхиальная астма у взрослых: клинические рекомендации. М.: Атмосфера; 2002: 130– 155.; Kuyper L.M., Pare P.D., Hogg J.C. et al. Characterization of airway plugging in fatal asthma. Am. J. Med. 2003; 115 (1): 6–11. DOI:10.1016/s0002-9343(03)00241-9.; National library of Medicine. Expert panel report 3: Guidelines for the diagnosis and management of asthma: Clinical practice guidelines. 2007. Available at: https://www.ncbi.nlm.nih.gov/books/NBK7232/; Grunfeld A., FitzGerald J. Discharge considerations for adult asthmatic patients treated in emergency departments. Can. Respir. J. 1996; 3 (5): 322–327. DOI:10.1155/1996/254627.; Edmonds M.L., Milan S.J., Brenner B.E. et al. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst. Rev. 2012; (12): CD002316. DOI:10.1002/14651858.CD002316.pub2.; Rowe B.H., Bota G.W., Fabris L. et al. Inhaled budesonide in addition to oral steroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999; 281 (22): 2219–2226. DOI:10.1001/jama.281.22.2119.; Schatz M., Rachelefsky G., Krishnan J.A. Follow-up after acute asthma episodes: what improves future outcomes? Proc. Am. Thorac. Soc. 2009; 6 (4): 386–393. DOI:10.1513/pats.p09st6.; Jaffuel D., Fabry-Vendrand C., Darnal E. et al. Perception of oral corticosteroids in adult patients with asthma in France. J. Asthma. 2021; 58 (7): 946–957. DOI:10.1080/02770903.2020.1748048.; Beckhaus A.A., Riutort M.C., Castro-Rodriguez J.A. Inhaled versus systemic corticosteroids for acute asthma in children: a systematic review. Pediatr. Pulmonol. 2014; 49 (4): 326–334. DOI:10.1002/ppul.22846.; Wilson N.M., Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch. Dis. Child. 1990; 65 (4): 407–410. DOI:10.1136/adc.65.4.407.; Su X.M., Yu N., Kong L.F., Kang J. Effectiveness of inhaled corticosteroids in the treatment of acute asthma in children in the emergency department: a meta-analysis. Ann. Med. 2014; 46 (1): 24–30. DOI:10.3109/07853890.2013.859855.; Rohrer V., Schmidt-Trucksäss A. [Impact of exercise, sport and rehabilitation therapy in asthma and COPD]. Ther. Umsch. 2014; 71 (5): 295–300. DOI:10.1024/0040-5930/a000516 (in German).; Hennenberger P.K., Liang X., Lilienberg L. et al. Occupational exposures associated with severe exacerbation of asthma. Int. J. Tuberc. Lung. Dis. 2015; 19 (2): 244–250. DOI:10.5588/ijtld.14.0132.; Oland A.A., Booster G.D., Bender B.G. Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children. World Allergy Organ. J. 2017; 10 (1): 35. DOI:10.1186/s40413-017-0169-9.; Aarniala B.S., Poussa T., Kvarnström J. et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000; 320 (7238): 827–832. DOI:10.1136/bmj.320.7238.827.; Hasegawa K., Tsugawa Y., Lopez B.L. et al. Body mass index and risk of hospitalization among adults presenting with asthma exacerbation to the emergency department. Ann. Am. Thorac. Soc. 2014; 11 (9): 1439–1444. DOI:10.1513/AnnalsATS.201406-270BC.; Gamble J., Stevenson M., Heaney L.G. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir. Med. 2011; 105 (9): 1308–1315. DOI:10.1016/j.rmed.2011.03.019.; Wenzel S. Severe asthma in adults. Am. J. Respir. Crit. Care Med. 2005; 172 (2): 149–160. DOI:10.1164/rccm.200409-1181PP.; Petsky H.L., Cates C.J., Lasserson T.J. et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012; 67 (3): 199–208. DOI:10.1136/thx.2010.135574.; Wang Y., Wang C.Z., Lin K.X. et al. Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate to severe asthma. Respirology. 2005; 10 (2): 189–195. DOI:10.1111/j.1440-1843.2005.00697.x.; Murphy V.E., Gibson P.G. Asthma in pregnancy. Clin. Chest Med. 2011; 32 (1): 93–110. DOI:10.1016/j.ccm.2010.10.001.; Dombrowski M.P., Schatz M., Wise R. et al. Asthma during pregnancy. Obstet. Gynecol. 2004; 103 (1): 5–12. DOI:10.1097/01.AOG.0000103994.75162.; 168. Zacharasiewicz A. Maternal smoking in pregnancy and its influence on childhood asthma. ERJ Open Res. 2016; 2 (3): 00042–2016. DOI:10.1183/23120541.00042-2016.; Eltonsy S., Forget A., Blais L. Beta2-agonists use during pregnancy and the risk of congenital malformations. Birth. Defects Res. A Clin. Mol. Teratol. 2011; 91 (11): 937–947. DOI:10.1002/bdra.22850.; Schatz M. Asthma treatment during pregnancy. What can be safely taken? Drug Saf. 1997; 16 (5): 342–350. DOI:10.2165/00002018-199716050-00005.; Lim A., Stewart K., König K., George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann. Pharmacother. 2011; 45 (7-8): 931–945. DOI:10.1345/aph.1P764.; NAEPP Expert Panel Report. Managing asthma during pregnancy: recommendations for pharmacologic treatment – 2004 update. J. Allergy Clin. Immunol. 2005; 115 (1): 34–46. DOI:10.1016/j.jaci.2004.10.023.; Wendel P.J., Ramin S.M., Barnett-Hamm C. et al. Asthma treatment in pregnancy: a randomized controlled study. Am. J. Obstet Gynecol. 1996; 175 (1): 150–154. DOI:10.1016/s0002-9378(96)70265-x.; Giles W., Murphy V. Asthma in pregnancy: a review. Obstet. Med. 2013; 6 (2): 58–63. DOI:10.1258/OM.2012.120008.; Michaud P.A., Suris J.C., Viner R. The adolescent with a chronic condition: epidemiology, developmental issues and health care provision. Geneva: World Health Organization; 2007. Available at: https://apps.who.int/iris/handle/10665/43775?locale-attribute=ru&-mode=full; Baur X., Sigsgaard T., Aasen T.B. et al. Guidelines for the management of work-related asthma. Eur. Respir. J. 2012; 39 (3): 529–545. DOI:10.1183/09031936.00096111.; Henneberger P.K., Patel J.R., de Groene G.J. et al. The effectiveness of removal from exposure and reduction of exposure for managing occupational asthma: summary of an updated Cochrane systematic review. Am. J. Ind. Med. 2020; 64 (3): 165–169. DOI:10.1002/ajim.23208.; Papadopoulos N.G., Arakawa H., Carlsen K.H. et al. International consensus on (ICON) pediatric asthma. Allergy. 2012; 67 (8): 976–997. DOI:10.1111/j.1398-9995.2012.02865.x.; Баранов А.А., Хаитов Р.М., ред. Аллергология и иммунология: клинические рекомендации для педиатров. 3-е изд. М.: Союз педиатров России; 2011; Zeiger R.S., Schatz M., Zhang F. et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J. Allergy Clin. Immunol. 2011; 128 (2): 412–414. DOI:10.1016/j.jaci.2011.06.008.; Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556. DOI:10.1016/j.jaci.2006.01.011.; Schatz M., Mosen D.M., Kosinski M. et al. Validity of the asthma control test completed at home. Am. J. Manag. Care. 2007; 13 (12): 661–667.; Liu A.H., Zeiger R., Sorkness C. et al. Development and cross-sectional validation of the childhood asthma control test. J. Allergy Clin. Immunol. 2007; 119 (4): 817–825. DOI:10.1016/j.jaci.2006.12.662.; Juniper E.F., O’Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14 (4): 902–907. DOI:10.1034/j.1399-3003.1999.14d29.x.; https://journal.pulmonology.ru/pulm/article/view/4109

Availability: https://journal.pulmonology.ru/pulm/article/view/4109
https://doi.org/10.18093/0869-0189-2022-32-3-393-447

Experience with the triple fixed combination in patients with chronic obstructive pulmonary disease ; Опыт применения тройной фиксированной комбинации у пациентов с хронической обструктивной болезнью легких

Authors: I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina, N. V. Gordeeva, И. В. Демко, М. Г. Мамаева, Е. А. Собко, А. Ю. Крапошина, Н. В. Гордеева

Source: Meditsinskiy sovet = Medical Council; № 21-1 (2021); 80-85 ; Медицинский Совет; № 21-1 (2021); 80-85 ; 2658-5790 ; 2079-701X

Subject Terms: ингаляционные глюкокортикостероиды, blood eosinophils, long-acting beta-agonists, long-acting anticholinergics, inhaled glucocorticosteroids, эозинофилы крови, длительно действующие β2-агонисты, длительно действующие антихолинергические препараты

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6610/5987; Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin D.V., Manakov L.G., Antonini P. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. https://doi. org/10.2147/copd.s67283.; Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М.; 2018. 76 с. Режим доступа: https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf.; Авдеев С.Н. Профилактика обострений хронической обструктивной болезни легких Пульмонология. 2016;26(5):591–603. https://doi.org/10.18093/0869-0189- 2016-26-5-591-603.; Burgel P.R. Des définitions aux phénotypes de BPCO. Presse Med. 2014;43(12 Pt 1): 1337–1343. https://doi.org/10.1016/j.lpm.2014.09.004.; Архипов В.В., Архипова Д.Е., Стукалина Е.Ю., Лазарев А.А. Частота встречаемости отдельных фенотипов хронической обструктивной болезни легких в Российской Федерации, их характеристики и подходы к лечению. Практическая пульмонология. 2016;(3):20–25. Режим доступа: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_3_2016_20.pdf.; Lange P., Halpin D.M., O’Donnell D.E., MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3– 12. https://doi.org/10.2147/COPD.S85976.; Визель А.А., Визель И.Ю., Бакунина Е.А. Хроническая обструктивная болезнь легких современные подходы к терапии. Медицинский совет. 2016;(15):6–10. https://doi.org/10.21518/2079-701X-2016-15-6-10.; Свидерская Л.Н., Симакова В.М., Демко И.В., Хендогина В.Т., Кудрявцева А.Н., Третьяк Т.В. и др. Сравнительная оценка организации контроля доступности и качества оказания медицинской помощи в условиях краевой консультативной поликлиники. Сибирское медицинское обозрение. 2016;(5):53–64. Режим доступа: https://smr.krasgmu.ru/journal/1629_53.pdf.; Calverley P., Vlies B. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21(4):581–589. https://doi.org/10.1111/resp.12690.; Stockley R.A., Chopra N., Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006;61(2):122–128. https://doi. org/10.1136/thx.2004.033266.; Jones P.W., Bosh T.K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155(4):1283–1289. https://doi.org/10.1164/ ajrccm.155.4.9105068.; Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L. et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. https://doi.org/10.1378/chest.11-2231.; Feldman G., Siler T., Prasad N., Jack D., Piggott S., Owen R. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11. https://doi.org/10.1186/1471-2466-10-11.; Koch A., Pizzichini E., Hamilton A., Hart L., Korducki L., De Salvo M.C. et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat (R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. https://doi.org/10.2147/COPD.S62502.; Dahl R., Chung K.F., Buhl R., Magnussen H., Nonikov V., Jack D. et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. https://doi.org/10.1136/thx.2009.125435.; Korn S., Kerwin E., Atis S., Amos C., Owen R., Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719–726. https://doi.org/10.1016/j.rmed.2011.02.008.; Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W. et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725. https://doi.org/10.1136/thx.2010.136077.; Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. https://doi.org/10.1056/NEJMoa0805800.; Celli B., Decramer M., Kesten S., Liu D., Mehra S., Tashkin D.P. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955. https://doi.org/10.1164/ rccm.200906-0876OC.; Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(7):CD009285. https://doi. org/10.1002/14651858.CD009285.pub2.; Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(9):CD009552. https://doi.org/10.1002/14651858.CD009552.pub2.; Celli B., Crater G., Kilbride S., Mehta R., Tabberer M., Kalberg C.J. et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;45(5):981–991. https://doi.org/10.1378/chest.13-1579.; Trivedi R., Richard N., Mehta R., Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81. https://doi. org/10.1183/09031936.00033213.; D’Urzo A., Kerwin E., Overend T., D’Andrea P., Chen H., Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2014;30(3):493–508. https://doi.org/10.1185/03007995. 2013.858618.; Chanez P., Burge P.S., Dahl R., Creemers J., Chuchalin A., Lamarca R. et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23(1):15–21. https://doi.org/10.1016/j.pupt.2009.08.001.; Bateman E.D., Ferguson G.T., Barnes N., Gallagher N., Green Y., Henley M., Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. https://doi.org/10.1183/09031936.00200212.; Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. https://doi.org/10.1016/S2213-2600(14)70065-7.; Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G. et al. Tiotropium and olodaterol fixed-dose combination versus monocomponents in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. https://doi.org/10.1183/09031936.00136014.; Latorre M., Novelli F., Vagaggini B., Braido F., Papi A., Sanduzzi A. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2- agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm Pharmacol Ther. 2015;30:44–50. https://doi. org/10.1016/j.pupt.2014.10.006.; Nannini L.J., Poole P., Milan S.J., Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826. https://doi.org/10.1002/14651858.CD006826.; Spencer S., Evans D.J., Karner C., Cates C.J. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;10:CD007033. https://doi.org/10.1002/14651858.CD007033.; Lipson D.A., Barnacle H., Birk R., Brealey N., Locantore N., Lomas D.A. et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438–446. https://doi.org/10.1164/ rccm.201703-0449OC.

Availability: https://www.med-sovet.pro/jour/article/view/6610
https://doi.org/10.21518/2079-701X-2021-21-1-80-85

Место фиксированной комбинации индакатерола, гликопиррония и мометазона фуроата в терапии бронхиальной астмы. Заключение Совета экспертов Российского респираторного общества ; The position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society

Authors: Aisanov, Zaurbek R., Avdeev, Sergey N., Belevskiy, Andrey S., Vizel', Aleksandr A., Emel'yanov, Aleksandr V., Ignatova, Galina L., Kurbacheva, Oksana M., Leshchenko, Igor' V., Nenasheva, Natal'ya M., Ovcharenko, Svetlana I., Sinopal'nikov, Aleksandr I., Titova, Ol'ga N., Айсанов, З. Р., Авдеев, С.Н., Белевский, А. С., Визель, А. А., Емельянов, А. В., Игнатова, Г. Л., Курбачева, О. М., Лещенко, И. В., Ненашева, Н. М., Овчаренко, С. И., Синопальников, А. И., Титова, О. Н.

Subject Terms: BRONCHIAL ASTHMA, CONTROL, EXACERBATION, INDACATEROL, GLYCOPYRRONIUM, MOMETASONE, BREEZHALER®, LONG-ACTING Β2-AGONIST/INHALED CORTICOSTEROID, LONG-ACTING ANTICHOLINERGICS, IRIDIUM, ARGON, БРОНХИАЛЬНАЯ АСТМА, КОНТРОЛЬ, ОБОСТРЕНИЕ, ИНДАКАТЕРОЛА АЦЕТАТ, ГЛИКОПИРРОНИЙ, МОМЕТАЗОНА ФУРОАТ, БРИЗХАЛЕР®, ДЛИТЕЛЬНО ДЕЙСТВУЮЩИЕ Β2-АГОНИСТЫ / ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, ДЛИТЕЛЬНО ДЕЙСТВУЮЩИЕ АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ

File Description: application/pdf

Relation: Пульмонология; http://elib.usma.ru/handle/usma/4826

Availability: http://elib.usma.ru/handle/usma/4826

Современные возможности терапии ингаляционными глюкокортикостероидами пациентов с хронической обструктивной болезнью легких ; Current opportunities of inhaled corticosteroid therapy in patients with chronic obstructive pulmonary disease

Authors: Leshchenko, Igor' V., Meshcheryakova, Anastasiya S., Лещенко, И. В., Мещерякова, А. С.

Subject Terms: CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INHALED CORTICOSTEROIDS, LONG-ACTING BRONCHODILATORS, EFFICACY, INHALATION DEVICE, ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ, ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, ДЛИТЕЛЬНО ДЕЙСТВУЮЩИЕ БРОНХО-ДИЛАТАТОРЫ, ЭФФЕКТИВНОСТЬ, ИНГАЛЯЦИОННОЕ УСТРОЙСТВО

File Description: application/pdf

Relation: Пульмонология; http://elib.usma.ru/handle/usma/4820

Availability: http://elib.usma.ru/handle/usma/4820

The position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society ; Место фиксированной комбинации индакатерола, гликопиррония и мометазона фуроата в терапии бронхиальной астмы. Заключение Совета экспертов Российского респираторного общества

Authors: Z. R. Aisanov, S. N. Avdeev, A. S. Belevskiy, A. A. Vizel', A. V. Emel'yanov, G. L. Ignatova, O. M. Kurbacheva, I. V. Leshchenko, N. M. Nenasheva, S. I. Ovcharenko, A. I. Sinopal'nikov, O. N. Titova, З. Р. Айсанов, С. Н. Авдеев, А. С. Белевский, А. A. Визель, А. В. Емельянов, Г. Л. Игнатова, О. М. Курбачева, И. В. Лещенко, Н. М. Ненашева, С. И. Овчаренко, А. И. Синопальников, О. Н. Титова

Contributors: The Expert Council of the Russian Respiratory Society was held with the support of Novartis Pharma LLC. The representatives of Novartis Pharma LLC did not participate in the writing of this article, are not responsible for the content of the article, and are not responsible for any possible financial or other agreements with any third parties related to this article. The opinion of Novartis Pharma LLC may differ from the opinion of the author of the article and the editorial board., Совет экспертов Российского респираторного общества проведен при поддержке Общества с ограниченной ответственностью «Новартис Фарма». В написании настоящей статьи представители Общества с ограниченной ответственностью «Новартис Фарма» не принимали участия, не несут ответственности за содержание статьи и любые возможные, относящиеся к данной статье договоренности либо финансовые соглашения с любыми третьими лицами. Мнение Общества с ограниченной ответственностью «Новартис Фарма» может отличаться от мнения авторов статьи и редакции.

Source: PULMONOLOGIYA; Том 31, № 1 (2021); 66-74 ; Пульмонология; Том 31, № 1 (2021); 66-74 ; 2541-9617 ; 0869-0189

Subject Terms: ARGON, control, exacerbation, indacaterol, glycopyrronium, mometasone, Breezhaler®, long-acting β 2 -agonist/inhaled corticosteroid, long-acting anticholinergics, IRIDIUM, контроль, обострение, индакатерола ацетат, гликопирроний, мометазона фуроат, Бризхалер®, длительно действующие β 2 -агонисты / ингаляционные глюкокортикостероиды, длительно действующие антихолинергические препараты

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2268/1818; Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990—2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5 (9): 691—706. DOI:10.1016/S2213-2600(17)30293-X.; Chuchalin A., Khaltaev N., Antonov N. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963—974. DOI:10.2147/COPD.S67283.; Global Initiative for Asthma. 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ [Accessed: July 17, 2020].; Stanford R.H., Gilsenan A.W., Ziemiecki R. et al. Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J. Asthma. 2010; 47 (3): 257—262. DOI:10.3109/02770900903584019.; Buhl R., Heaney L.G., Loefroth E. et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting p2-agonist in UK primary care settings. Respir. Med. 2020; 162: 105859. DOI:10.1016/j.rmed.2019.105859.; Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836—844. DOI:10.1164/rccm.200401-033OC.; Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI:10.1038/npjpcrm.2014.23.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: Novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26 (1): 145—155. DOI:10.1016/j.pupt.2012.07.003.; Alagha K., Palot A., Sofalvi T. et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic. Dis. 2014; 5 (2): 85—98. DOI:10.1177/2040622313518227.; Kerstjens H.A.M., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198—207. DOI:10.1056/NEJMoa1208606.; Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2015; (5): CD011721. DOI:10.1002/14651858.CD011721.; Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Once-daily, single-inhaler mometasone—indacaterol—glycopyrronium versus mometasone—indacaterol or twice-daily fluti-casone—salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir. Med. 2020; 8 (10): 1000—1012. DOI:10.1016/S2213-2600(20)30190-9.; Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI:10.1016/j.rmed.2020.106021.; Papi A., Humbert M., Kostikas K. et al. Medium-dose inda-caterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with high-dose indacaterol/mometasone furoate and salmeterol/fluti-casone and reduces exacerbation rates versus high-dose sal-meterol/fluticasone in moderate-to-severe asthma: The IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.; Российское респираторное общество. Бронхиальная астма: Федеральные клинические рекомендации. 2019. Доступно на: http://spulmo.ru/upload/kr_bronhastma_2019.pdf [Дата обращения 17.07.20].; Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042— 1050. DOI:10.1183/09031936.00074905.; Cowie R.L., Giembycz M.A., Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin. Pharmacother. 2009; 10 (12): 2009—2014. DOI:10.1517/14656560903078428.; Donohue J.F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting p2-agonists as monotherapy for chronic obstructive pulmonary disease: a network metaanalysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367381. DOI:10.2147/COPD.S119908.; Blais C.M., Davis B.E., Cockcroft D.W. The effect of gly-copyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir. Res. 2017; 18 (1): 146. DOI:10.1186/s12931-017-0628-4.; Sanders M.J. Guiding inspiratory flow: development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm. Med. 2017; 2017: 1495867. DOI:10.1155/2017/1495867.; Altman P., Wehbe L., Dederichs J. et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm. Med. 2018; 18 (1): 100. DOI:10.1186/s12890-018-0662-0.; Dolovich M.A., Kuttler A., Dimke T.J., Usmani O.S. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. Int. J. Pharm. 2019; 1: 100018. DOI:10.1016/j.ijpx.2019.100018.; Sanduzzi A., Balbo P., Candoli P. et al. COPD: adherence to therapy. Multidiscip. Respir. Med. 2014; 9: 60. DOI:10.1186/2049-6958-9-60.; Price D., Keininger D.L., Viswanad B. et al. Factors associated with appropriate inhaler use in patients with COPD -lessons from the REAL survey [Erratum]. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2253-2254. DOI:10.2147/COPD.S178410.; Визель А.А., Резяпова А.И., Визель И.Ю., Амиров Н.Б. К поиску «идеального» средства доставки лекарственных веществ при обструктивных заболеваниях органов дыхания: наблюдательное исследование в сравнении с данными литературы. Вестник современной клинической медицины. 2020; 13 (2): 22-30. DOI:10.20969/VSKM.2020.13(2).22-30.; Vaidya S.S., Khindri S., Robinson J. et al. Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects. Eur. Respir. J. 2012; 40 (Suppl. 56): 2145. Available at: https://erj.ersjournals.com/content/erj/40/Suppl_56/P2145.full.pdf; Buhl R., Tanase A.M., Hosoe M. et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulm. Pharmacol. Ther. 2020; 62: 101919. DOI:10.1016/j.pupt.2020.101919.; Saini S.D., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care. 2009; 15 (6): e22-33.; Beier J., Watz H., Scholz V. The efficacy of the combination indacaterol/glycopyrronium/mometasone furoate is independent of time of dosing in patients with asthma. Am. J. Respir. Crit. Care Med. 2019; 199: A1277. DOI:10.1164/ajrc-cm-conference.2019.199.1_MeetingAbstracts.A1277.; Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737-1749. DOI:10.1016/S0140-6736(19)32215-9.; Lee L.A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 2021; 9 (1): 69-84. DOI:10.1016/S2213-2600(20)30389-1.; https://journal.pulmonology.ru/pulm/article/view/2268

Availability: https://journal.pulmonology.ru/pulm/article/view/2268
https://doi.org/10.18093/0869-0189-2021-31-1-66-74

The role of anti-inflammatory treatment in achieving of bronchial asthma control in children (bibliographical review) ; Роль противовоспалительной терапии в достижении контроля над бронхиальной астмой у детей (обзор литературы) ; Роль протизапальної терапії в досягненні контролю бронхіальної астми в дітей (огляд літератури)

Authors: Сажин, С.

Source: Bukovinian Medical Herald; Vol. 14 No. 1 (53) (2010); 147-151 ; Буковинский медицинский вестник; Том 14 № 1 (53) (2010); 147-151 ; Буковинський медичний вісник; Том 14 № 1 (53) (2010); 147-151 ; 2413-0737 ; 1684-7903

Subject Terms: bronchial asthma, antiinflammatory therapy, children, inhalation glucocorticosteroids, бронхиальная астма, противовоспалительная терапия, дети, ингаляционные глюкокортикостероиды, бронхіальна астма, протизапальна терапія, діти, інгаляційні глюкокортикостероїди

File Description: application/pdf

Relation: http://e-bmv.bsmu.edu.ua/article/view/243748/241723

Availability: http://e-bmv.bsmu.edu.ua/article/view/243748

The role of anti-inflammatory treatment in achieving of bronchial asthma control in children (bibliographical review)

Source: Bukovinian Medical Herald; Vol. 14 No. 1 (53) (2010); 147-151
Буковинский медицинский вестник; Том 14 № 1 (53) (2010); 147-151
Буковинський медичний вісник; Том 14 № 1 (53) (2010); 147-151

Subject Terms: bronchial asthma, antiinflammatory therapy, children, inhalation glucocorticosteroids, бронхиальная астма, противовоспалительная терапия, дети, ингаляционные глюкокортикостероиды, бронхіальна астма, протизапальна терапія, діти, інгаляційні глюкокортикостероїди, 3. Good health

File Description: application/pdf

Access URL: http://e-bmv.bsmu.edu.ua/article/view/243748

First triple therapy in one inhaler for COPD patients: treatment approach (scientific data overview) ; Первая тройная фиксированная комбинация для пациентов с хронической обструктивной болезнью легких: место в терапии (обзор научных данных)

Authors: S. N. Avdeev, Z. R. Aisanov, A. V. Emelyanov, С. Н. Авдеев, З. Р. Айсанов, А. В. Емельянов

Contributors: This publication is supported by GlaxoSmithKline Trading Joint Stock Company, according to the current legislation of Russian Federation and Good Publication Practice standards, Статья подготовлена при поддержке компании Акционерное общество «ГлаксоСмитКляйн Трейдинг» в соответствии с действующим законодательством Российской Федерации и принципами добросовестной практики научных публикаций (Good Publication Practice)

Source: PULMONOLOGIYA; Том 30, № 6 (2020); 813-821 ; Пульмонология; Том 30, № 6 (2020); 813-821 ; 2541-9617 ; 0869-0189

Subject Terms: Треледжи Эллипта, COPD maintenance treatment, triple therapy, inhaled corticosteroid, triple combinations, COPD exacerbations, Trelegy Ellipta, поддерживающая терапия ХОБЛ, тройная терапия, ингаляционные глюкокортикостероиды, тройные комбинации, обострения ХОБЛ

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2217/1805; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available at: https://goldcopd.org/wp-con-tent/uploаds/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf [Accessed: May 11, 2020].; Antoniu S.A., Carone M. Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. Expert Rev. Pharmacoecon. Outcomes Res. 2013; 13 (2): 187-189. DOI:10.1586/erp.13.9.; Российское респираторное общество. Клинические рекомендации. Хроническая обструктивная болезнь легких. 2018. Доступно на: http://spulmo.ru/obrazovatel-nye-resursy/federalnye-klinicheskie-rekomendatsii/ [Дата обращения: 21.10.19].; Nici L., Mammen M.J., Charbek E. et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020; 201 (9): e56-69. DOI:10.1164/rccm.202003-0625ST.; Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (4): 297-304; discussion 311-312. DOI:10.1513/pats.200504-043SR.; Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 2011; 105 (3): 435-441. DOI:10.1016/j.rmed.2010.09.006.; Babu K.S., Morjaria J.B. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther. Adv. Chronic. Dis. 2017; 8 (4-5): 81-91. DOI:10.1177/2040622317700822.; Salmon M., Luttmann M.A., Foley J.J. et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J. Pharmacol. Exp. Ther. 2013; 345 (2): 260-270. DOI:10.1124/jpet.112.202051.; Trivedi R., Richard N., Mehta R., Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur. Respir. J. 2014; 43 (1): 72-81. DOI:10.1183/09031936.00033213.; Pleasants R.A., Wang T., Gao J. et al. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016; 76 (3): 343-361. DOI:10.1007/s40265-015-0532-5.; Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 719-730. DOI:10.2147/COPD.S102494.; Malerba M., Nardin M., Santini G. et al. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther. Adv. Respir. Dis. 2018; 12: 175346661876 0779. DOI:10.1177/1753466618760779.; Hanania N.A., Feldman G., Zachgo W et al. The efficacy and safety of the novel long-acting в2 agonist vilanterol in patients with COPD: a randomised placebo-controlled trial. Chest. 2012; 142 (1): 119-127. DOI:10.1378/chest.11-2231.; Jiang Z., Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2016; 37: 1-8. DOI:10.1016/j.pupt.2016.01.002.; Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435-442. DOI:10.1016/S2213-2600(15)00106-X.; Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting 0-2 agonist efficacy in COPD. Thorax. 2016; 71 (2):118-125. DOI:10.1136/tho-raxjnl-2015-207021.; Daley-Yates P.T. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br. J. Clin. Pharmacol. 2015; 80 (3): 372-380. DOI:10.1111/bcp.12637.; Rossios C., To Y., To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur. J. Pharmacol. 2011; 670 (1): 244-251. DOI:10.1016/j.ejphar.2011.08.022.; van Boven J.F.M., Chavannes N.H., van der Molen T. et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir. Med. 2014; 108 (1): 103-113. DOI:10.1016/j.rmed.2013.08.044.; Siler T.M., Kerwin E., Sousa A.R. et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomised studies. Respir. Med. 2015; 109 (9): 1155-1163. DOI:10.1016/j.rmed.2015.06.006.; Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438-446. DOI:10.1164/rccm.201703-0449OC.; Pascoe S.J., Lipson D.A., Locantore N. et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur. Respir. J. 2016; 48 (2): 320-330. DOI:10.1183/13993003.02165-2015.; Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671-1680. DOI:10.1056/NEJMoa1713901.; Lipson D.A., Crim C., Criner G.J. et al. Reduction in allcause mortality with fluticasone furoate/umeclidinium/ vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2020; 201 (12): 1508-1516. DOI:10.1164/rccm.201911-2207OC.; https://journal.pulmonology.ru/pulm/article/view/2217

Availability: https://journal.pulmonology.ru/pulm/article/view/2217
https://doi.org/10.18093/0869-0189-2020-30-6-813-821

Rational therapy of asthma in children with inhaled corticosteroids

Authors: N. A. Geppe, N. G. Kolosova, S. I. Shatalina

Source: Медицинский совет, Vol 1, Iss 1, Pp 63-67 (2016)

Subject Terms: budesonide, budesonide/formoterol, будесонид/формотерол, дети, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, children, Medicine, бронхиальная астма, bronchial asthma, inhaled corticosteroids, ингаляционные глюкокортикостероиды, будесонид

Access URL: https://www.med-sovet.pro/jour/article/download/11/11
https://doaj.org/article/656b91dbbf104dba8482e96cd1b5d5df
https://cyberleninka.ru/article/n/ratsionalnaya-terapiya-ingalyatsionnymi-kortikosteroidami-pri-bronhialnoy-astme-u-detey
https://www.med-sovet.pro/jour/article/view/11/11
https://cyberleninka.ru/article/n/ratsionalnaya-terapiya-ingalyatsionnymi-kortikosteroidami-pri-bronhialnoy-astme-u-detey/pdf

Распространенность бронхиальной астмы легкого течения в регионах РФ и оценка различных схем медикаментозной терапии (по результатам наблюдательного исследования): The prevalence of mild bronchial asthma in various regions of Russian Federation and evaluation of various drug therapy regimens (observational study results)

Source: Вопросы обеспечения качества лекарственных средств.

Subject Terms: short-acting beta 2-agonist, ингаляционные глюкокортикостероиды (ИГКС), бета-2-агонисты короткого действия (КДБА), asthma bronchial, бронхиальная астма, inhaled corticosteroid, 3. Good health, mild asthma

Лечение синдрома Крупа у детей на догоспитальном этапе ; Treatment of syndrome of Сroup in children on prehospital stage

Authors: Salova, А. L., Mozzhukhina, L. I., Kogut, T. A., Chelnokova, O. G., Салова, А. Л., Мозжухина, Л. И., Когут, Т. А., Челнокова, О. Г.

Subject Terms: STENOSING LARYNGOTRACHEITIS, TREATMENT, INHALED GLUCOCORTICOSTEROIDS, PHARMACOECONOMICS, СТЕНОЗИРУЮЩИЙ ЛАРИНГОТРАХЕИТ, ЛЕЧЕНИЕ, ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, ФАРМАКОЭКОНОМИКА

File Description: application/pdf

Relation: Уральский медицинский журнал. 2019. Т. 170, № 2.; http://elib.usma.ru/handle/usma/12545

Availability: http://elib.usma.ru/handle/usma/12545